What Megace ES Treats: Main Uses and Benefits

The core therapeutic purpose of Megace ES is relevant for addressing symptoms related to systemic imbalance, specifically the debilitating effects of significant, involuntary weight loss and profound loss of appetite that generally accompany severe, chronic illnesses.

This medication is commonly applied in situations involving certain distressing symptoms, primarily applied across domains where additional symptomatic support is needed. It is used for the management of anorexia, cachexia (wasting syndrome), and unexplained significant weight loss. Its relevance is seen in clinical scenarios like AIDS-related wasting syndrome and cancer-associated anorexia-cachexia syndrome (CACS).

The medication is applied in scenarios where additional management of discomfort is required. It may assist with increasing the appetite. This therapeutic action supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability. It is indicated for the treatment of anorexia and cachexia.

It is often used during phases when symptoms become more noticeable, where supportive symptom management is appropriate in palliative care settings.

“It may assist with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Severe Appetite Loss (Anorexia)

Megace ES (Megestrol Acetate) is officially indicated for use in adult patients with Acquired Immunodeficiency Syndrome (AIDS) who are experiencing anorexia, cachexia, or unexplained significant weight loss. Its eligibility profile is defined by strict regulatory categories.

Absolute Contraindications

The medicine must not be used by certain populations. Megace ES is contraindicated in patients with a known or suspected pregnancy due to the potential for fetal harm; females of reproductive potential must use effective contraception. It is also contraindicated in patients with a history of hypersensitivity to megestrol acetate or any other component of the formulation.

Age-Group and Conditional Restrictions

Age Group	Regulatory Status
Pediatric Use	Safety and effectiveness have not been established.
Geriatric Use	Use requires cautious dose selection due to potential for decreased organ function.

Use requires caution in patients with a history of thromboembolic disease (blood clots) and in patients with pre-existing diabetes mellitus, which may be exacerbated. Patients with impaired renal function may require monitoring because the drug is substantially excreted by the kidney. Furthermore, the medicine is not intended for prophylactic use to avoid weight loss.

Interactions with other medicines and products

Official regulatory documents define specific pharmacokinetic and pharmacodynamic interactions for Megestrol Acetate, the active ingredient in Megace ES, that affect the systemic exposure of co-administered medicines.

Documented Drug Interactions

Classification	Interacting Agents / Outcome Statement
Transporter-Mediated Exposure	Co-administration with Indinavir results in a significant decrease in the systemic exposure of Indinavir, an outcome that requires considering a higher Indinavir dose.
Pharmacodynamic Antagonism	Megestrol Acetate decreases the therapeutic efficacy of Insulin and other antidiabetic agents (e.g., Acarbose) due to a pharmacodynamic interaction that may impair glucose tolerance.
Exposure-Modifying Effects	The medication increases the effects of the anticoagulant Warfarin, necessitating close monitoring. Regulatory labeling states no dosage adjustment is warranted for Zidovudine or Rifabutin.

Food Interaction and Population Notes

The concentrated formulation of Megace ES can be administered without regard to meals, despite official documentation showing that a high-fat meal increases the systemic exposure of Megestrol Acetate (mean C max is increased by up to 48%).

Cautions regarding appropriate dose selection are noted for the elderly population due to the greater frequency of reduced cardiac, renal, or hepatic function, which may influence Megestrol Acetate exposure during concomitant therapy.

Megestrol acetate, a synthetic progestin and the active ingredient in Megace ES, acts primarily as an agonist at the nuclear progesterone receptor (PR), with a high relative binding affinity. This interaction causes the ligand-receptor complex to translocate into the cell nucleus, where it binds to specific hormone response elements on the DNA. This binding event modulates the transcription and expression of target genes, resulting in an alteration of cellular protein synthesis, particularly in reproductive tissues.

Downstream of the progesterone receptor activation, megestrol acetate exerts an antigonadotropic effect. This involves a negative feedback mechanism on the hypothalamic-pituitary-gonadal (HPG) axis, leading to suppression of luteinizing hormone (LH) release from the pituitary gland. This systemic modulation results in the inhibition of ovarian function and reduced endogenous estrogen synthesis.

Megestrol acetate also possesses agonist activity at the glucocorticoid receptor (GR) and has been shown to modulate the peripheral action and production of catabolic cytokines such as IL-6 and TNF-alpha, likely through interference with their signaling pathways.

Official Administration Guidelines for Megace ES

The administration of Megace ES Oral Suspension is governed by precise guidelines designed to ensure correct patient use and optimal delivery of the concentrated formula. The medicine is administered exclusively by the oral route. The standard regimen for adult use is a single daily dose of 625 mg, which corresponds exactly to 5 mL of the concentrated 125 mg/mL suspension. This dosage is the recommended amount for this use, administered only once daily.

The concentrated nature of the formulation demands specific procedural care during preparation and measurement. Before measuring, the bottle must be shaken well. Dosing must be conducted using a calibrated measuring device to ensure accurate volume delivery. This attention to detail is critical because Megace ES is not bioequivalent to, and therefore not interchangeable with, lower-concentration megestrol acetate suspensions or tablets on a simple milligram-to-milligram basis. The single daily dose can be taken with or without meals.

Regarding the duration of administration, guidelines state that the treatment should continue for a minimum of at least two months before the patient’s response is fully assessed. While general caution is advised for older adults due to the greater frequency of decreased organ function, no specific dose adjustment for geriatric patients or those with renal or hepatic impairment is detailed in the official labeling. Furthermore, specific dosing guidelines for pediatric patients have not been established.

Research Evidence / Overview of Studies

Bioequivalence and Pharmacokinetics

Studies were conducted to establish bioequivalence between the original megestrol acetate oral suspension (Megace OS) and the concentrated formulation, Megace ES. This research showed that the Megace ES dose of 625 mg achieved plasma concentrations equivalent to the 800 mg dose of the original Megace OS under fed conditions. The concentrated formulation utilizes NanoCrystal technology, which has been shown to result in significantly higher peak plasma levels in unfed patients compared to the conventional oral suspension.

Efficacy and Outcome Research

Clinical trials primarily evaluated megestrol acetate in patients with anorexia, cachexia, or unexplained significant weight loss associated with Acquired Immunodeficiency Syndrome (AIDS). Key findings from pivotal placebo-controlled studies included:

Outcome Parameter	Observation vs. Placebo (800 mg dose)
Weight Gain	Statistically significant increases in mean body weight
Appetite	Improved appetite reported by a greater percentage of treated patients
Body Composition	Increases in non-water body weight (lean body mass) observed

Special Populations

Research on the compound in special populations, such as pregnant or breastfeeding individuals, remains limited. Studies are currently underway in pediatric populations. Appropriate caution is advised for geriatric patients due to the greater frequency of age-related physiological changes that may affect drug metabolism.

Common questions about Megace ES (Progesterone) (FAQ)

---

Q: What is the main difference between Megace ES and the regular Megace suspension?

Megace ES is a specialized, highly concentrated formula of megestrol acetate, containing 125 mg per milliliter (mL). Official regulatory information states that this formulation is not interchangeable with the standard megestrol acetate suspension or tablets on a simple milligram-to-milligram basis. This concentrated formulation is designed to be administered in a smaller volume of liquid.

---

Q: What kind of rash or skin reaction might happen when taking Megace ES?

According to the official product information, rash is a common skin reaction, reported in a small percentage of patients taking the medication. Alopecia, which is the technical term for hair loss, is also listed as a common side effect of the medicine.

---

Q: What are the specific symptoms of Cushing's Syndrome that are linked to chronic use of Megace ES?

Chronic use of megestrol acetate has been linked to rare cases of Cushing's Syndrome due to the drug's effect on the adrenal glands. The symptoms associated with this condition may include a rounded face, fat buildup in the upper body (or neck area), and having thin skin that bruises easily.

---

Q: Is Megace ES used for cancer treatment or only for weight loss and appetite stimulation?

Megace ES oral suspension is officially indicated for treating anorexia, cachexia, or unexplained weight loss in adults with AIDS. Regulatory documents for the megestrol acetate tablet form state that it is also indicated for the palliative treatment of advanced breast and endometrial cancer.

---

Q: How quickly does Megace ES typically start to increase a person's appetite?

Studies and official information indicate that improvement in appetite may be noticed in up to three weeks of treatment. The patient's full response regarding weight gain is typically assessed after a minimum of two months of treatment.

---

Q: Can Megace ES be taken while using common forms of hormonal birth control?

The official label warns that females who are of reproductive potential must use an effective form of contraception during treatment and for a period after stopping the drug. This is due to the potential risk of fetal harm if the patient becomes pregnant.

---

Q: How long does Megace ES stay in the body after the last dose is taken?

The time it takes for the concentration of megestrol acetate to decrease by half (known as the plasma elimination half-life) is reported to range widely, generally from approximately 13 to 105 hours. The full elimination time can vary.

---

Q: What are the serious signs of a blood clot I should be aware of while taking this medicine?

The regulatory label warns of the risk of blood clots. Serious signs that require immediate medical attention include pain, swelling, or warmth in the leg. Signs of a potential lung clot include shortness of breath and chest pain.

---

Q: What are the recommendations for a patient who accidentally misses a dose of Megace ES?

Official information advises contacting a doctor or health care team for instructions if a dose is missed or if a patient vomits shortly after taking a dose. It is stated that taking two doses at the same time to make up for a missed dose is not recommended.

---

Q: Does Megace ES have the potential to cause fluid retention or swelling in the limbs?

Yes, official regulatory documents list edema (swelling) and peripheral edema (which is swelling of the ankles or feet) as potential adverse reactions associated with the use of this medicine.

---

Q: Can men taking Megace ES experience changes in sexual function or impotence?

Clinical trial data indicates that men taking this medicine may experience adverse reactions affecting sexual health. These effects include impotence (the inability to achieve or maintain an erection) and a decreased libido (sexual desire).

---

Q: Does Megace ES affect a woman's regular menstrual cycle, such as causing spotting or irregular periods?

Yes, because megestrol acetate is a hormonal compound, adverse reactions listed in the official documents may include breakthrough menstrual bleeding or irregular menstrual cycles/spotting.

---

Q: Is there a difference in how Megace ES is used for cachexia versus its use for certain cancers?

Megace ES oral suspension is indicated for anorexia/wasting in AIDS patients, which is a type of cachexia. The megestrol acetate tablet form is indicated for palliative treatment of advanced breast and endometrial cancer, showing a difference in the primary approved indications for the different formulations.

---

Q: How is the effectiveness of Megace ES in promoting weight gain typically monitored during a course of treatment?

It is advised that patients attend regular checks on progress with their care team. Assessment of the medication's effectiveness in promoting weight gain is typically conducted after a minimum of two months of regular use.

---

Q: Why does the medication sometimes cause side effects like hot flashes or sweating?

Official regulatory documents list both hot flashes and sweating as documented adverse reactions. These effects are listed as documented adverse reactions in the official product information.

---

Q: Can Megace ES cause a person to develop changes in their vision?

A change in vision has been reported as a less common side effect in the official patient information for megestrol acetate. Any changes in vision should be discussed with a healthcare provider.

---

Q: Does the generic version of the suspension have the same detailed warnings as the Megace ES brand?

According to regulatory requirements, generic drug formulations are generally required by the FDA to have the same detailed warnings and precautions as the brand reference drug, Megace ES.

---

Q: Can chronic Megace ES use cause a person to develop thinning skin or bruising easily?

This is a symptom associated with the rare occurrence of Cushing's Syndrome, which has been reported with chronic use of the drug. Thinning skin that bruises easily is part of the clinical picture linked to this potential endocrine effect.

Storage and Disposal Requirements for Megace ES Oral Suspension

Megace ES (megestrol acetate) oral suspension must be stored at Controlled Room Temperature, defined as 25 C (77 F), with temperature excursions permitted between 15 C to 30 C (59 F to 86 F). The regulatory labeling requires the product to be protected from heat.

Container and Handling

The suspension must be dispensed in a tight container and should be shaken well before using to ensure uniformity. For safety, the medication must be kept out of the sight and reach of children at all times.

Official Disposal

Unused or expired Megace ES and its container must be disposed of in accordance with applicable laws and regulations. Disposal must follow official local, state, and national guidelines, and care should be taken to avoid environmental release.